间变性淋巴瘤激酶-话题@MedSci

#间变性淋巴瘤激酶#

2篇内容 | 1173人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2179700, encodeId=2a9021e97003e, content=<a href='/topic/show?id=211e823029d' target=_blank style='color:#2F92EE;'>#肺腺癌#</a> <a href='/topic/show?id=d6bc231956' target=_blank style='color:#2F92EE;'>#ALK抑制剂#</a> <a href='/topic/show?id=3ae49e240b5' target=_blank style='color:#2F92EE;'>#间变性淋巴瘤激酶#</a>, objectTitle=KLC1/ALK重排肺腺癌胸膜转移患者对二三代ALK抑制剂原发耐药, objectType=article, longId=808529, objectId=0ac3808529ea, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-doctor-hand-with-pen-BWV9L2K.jpg, objectUrl=/article/show_article.do?id=0ac3808529ea, replyNumber=0, likeNumber=70, createdTime=2024-01-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=0ac3808529ea, moduleTitle=KLC1/ALK重排肺腺癌胸膜转移患者对二三代ALK抑制剂原发耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ac3808529ea)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2173456, encodeId=456221e34569a, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a> <a href='/topic/show?id=3ae49e240b5' target=_blank style='color:#2F92EE;'>#间变性淋巴瘤激酶#</a> <a href='/topic/show?id=70b2291294b' target=_blank style='color:#2F92EE;'>#免疫组织化学#</a> <a href='/topic/show?id=e01a8e24227' target=_blank style='color:#2F92EE;'>#荧光原位杂交#</a>, objectTitle=ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE：免疫组织化学和荧光原位杂交在检测非小细胞肺癌中间变性淋巴瘤激酶和ROS1基因重组方面的一致性, objectType=article, longId=803975, objectId=1b078039e56b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301015/1697393424174_4754896.jpeg, objectUrl=/article/show_article.do?id=1b078039e56b, replyNumber=0, likeNumber=118, createdTime=2023-12-07, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1b078039e56b, moduleTitle=ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE：免疫组织化学和荧光原位杂交在检测非小细胞肺癌中间变性淋巴瘤激酶和ROS1基因重组方面的一致性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b078039e56b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2004129, encodeId=ff482004129c7, content=<a href='/topic/show?id=3ae49e240b5' target=_blank style='color:#2F92EE;'>#间变性淋巴瘤激酶#</a>, objectTitle=中国间变性淋巴瘤激酶阳性、ROS1阳性非小细胞肺癌诊疗指南, objectType=article, longId=138096, objectId=5134138096d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5134138096d4, replyNumber=0, likeNumber=93, createdTime=2019-02-22, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5134138096d4, moduleTitle=中国间变性淋巴瘤激酶阳性、ROS1阳性非小细胞肺癌诊疗指南, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5134138096d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004128, encodeId=a7f6200412826, content=<a href='/topic/show?id=3ae49e240b5' target=_blank style='color:#2F92EE;'>#间变性淋巴瘤激酶#</a>, objectTitle=2016NICE技术评估指南：Crizotinib用于未经治疗的间变性淋巴瘤激酶（ALK）阳性的晚期非小细胞肺癌的治疗（TA406）发布, objectType=article, longId=81135, objectId=124781135a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=124781135a7, replyNumber=0, likeNumber=94, createdTime=2016-11-11, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=124781135a7, moduleTitle=2016NICE技术评估指南：Crizotinib用于未经治疗的间变性淋巴瘤激酶（ALK）阳性的晚期非小细胞肺癌的治疗（TA406）发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=124781135a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

间变性淋巴瘤激酶

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#肺腺癌# #ALK抑制剂# #间变性淋巴瘤激酶#

KLC1/ALK重排肺腺癌胸膜转移患者对二三代ALK抑制剂原发耐药

2024-01-06发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #ROS1# #间变性淋巴瘤激酶# #免疫组织化学# #荧光原位杂交#

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE：免疫组织化学和荧光原位杂交在检测非小细胞肺癌中间变性淋巴瘤激酶和ROS1基因重组方面的一致性

2023-12-07发表于上海

heli0118 (审核中...)

前往app查看评论内容

#间变性淋巴瘤激酶#

中国间变性淋巴瘤激酶阳性、ROS1阳性非小细胞肺癌诊疗指南

2019-02-22

heli0118 (审核中...)

前往app查看评论内容

#间变性淋巴瘤激酶#

2016NICE技术评估指南：Crizotinib用于未经治疗的间变性淋巴瘤激酶（ALK）阳性的晚期非小细胞肺癌的治疗（TA406）发布

2016-11-11

科室
- - 订阅+
  - 更多科室
工具
服务